Oppenheimer reiterated an Outperform rating on Five Prime Therapeutics (NASDAQ: FPRX), and raised the price target to $48.00 (from $45.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Notable 52-Week Highs and Lows 10/16: (GE) (FPRX) (ROCK) High; (PWR) (ZFGN) (SAVE) LowOctober 16, 2015 3:56 PM Market Wrap: Expected Fed Rate Hike Delay Boosts Markets; Citi, Goldman Mixed in Q3; Seagate Cuts OutlookOctober 15, 2015 5:26 PM Leerink Partners Remains Bullish on Five Prime Therapeutics (FPRX) Following announced Agreement with BMY October 15, 2015 4:06 PM Notable 52-Week Highs and Lows 10/15: (FPRX) (NKE) High; (STX) (MTW) (GRMN) LowOctober 15, 2015 3:26 PM Unusual 11 Mid-Day Movers 10/15: (FPRX) (AFMD) (DXCM) Higher; (IMPR) (VAC) (ACST) LowerOctober 15, 2015 12:54 PM Pre-Open Stock Movers 10/15: (FPRX) (BOFI) (DXCM) Higher; (IMPR) (MTW) (VRX) (STX) (GRMN) (HCA) (NFLX) Lower (more...)October 15, 2015 9:31 AM Five Prime Therapeutics (FPRX) Sees Windfall on Anti-CSF1R Collaboration Agreement (BMY)October 15, 2015 9:20 AM Five Prime Therapeutics (FPRX) Enters Collaboration with Bristol-Myers Squibb (BMY) Worth Up to $1.74BOctober 15, 2015 6:06 AM Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody ProgramOctober 15, 2015 4:05 AM Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody ProgramOctober 15, 2015 4:05 AM Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody ProgramOctober 15, 2015 4:00 AM Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody ProgramOctober 15, 2015 4:00 AM Bristol-Myers Squibb Enters into Exclusive Worldwide License and Collaboration Agreement with Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody ProgramOctober 15, 2015 4:00 AM